NextCure(NXTC) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Next@ure NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results – LNCB74 (B7-H4 ADC) GLP tox studies completed and targeting an IND application by year-end – NC410 combo with pembrolizumab ovarian cohort enrollment completed – Cash of approximately $86.4 million expected to fund operations into second half of 2026 BELTSVILLE, Md. – August 1, 2024 – NextCure, Inc. (Nasdaq: NXTC), a clinicalstage biopharmaceutical company committed to discovering and developing novel, ...